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Small dense LDL (sd-LDL) has recently emerged as an im-
portant coronary artery disease (CAD) risk factor. This study
was performed to investigate how LDL particle size is related
to CAD and acute coronary syndrome (ACS). Blood samples
were collected from 504 patients that underwent coronary
angiography to evaluate chest pain. The LDL particle size of
these samples was measured. The mean LDL particle size was
smaller in patients with angiographically proven CAD than in
the controls (26.41 ± 0.95 vs 26.73 ± 0.64 nm, p < 0.001),
and was negatively correlated with the Framingham risk score
(r = -0.121, p = 0.007). Patients with more extensive CAD had
smaller LDL particles. LDL particle size was also smaller in
patients with acute coronary syndrome as compared to non-
ACS patients (26.09 ± 1.42 vs 26.54 ± 0.63 nm, p = 0.011).
These results suggest that sd-LDL is independently associated
with the incidence and extent of CAD, and can be a risk factor
for the development of ACS in the Korean population.
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INTRODUCTION
The importance of low-density lipoprotein
(LDL) cholesterol in the development of athero-
sclerosis has long been recognized. Thus it is
logical that LDL cholesterol remains the primary
therapeutic target for coronary artery disease
(CAD) prevention. Nevertheless, an increasing
amount of research over the past decade has been
devoted to the heterogeneity of LDL particles and
the atherogenicity of lipids and lipoproteins other
than LDL. LDL heterogeneity, along with dietary
and genetic influences, is now well recognized as
an indicator of differences in lipoprotein composi-
tion, size, and metabolism.1-3 For these reasons,
small, dense low-density lipoprotein (sd-LDL) is
viewed as an important CAD risk factor.1,4,5
There are several proposed biochemical and
cellular mechanisms related to the sd-LDL athero-
genicity. For example, sd-LDL may reside in the
plasma longer,6-10 not bind the LDL receptor as
well, bind the scavenger receptor more avidly,11-14
be more susceptible to oxidation,15-17 have fewer
antioxidants in its core,18,19 enter the arterial wall
more easily,20,21 and bind to the glycosaminogly-
cans in the arterial wall more readily.22,23 The cel-
lular mechanisms include: an sd-LDL promotion
of endothelial cell dysfunction,24 induction of
greater PAI-1 (plasminogen activator inhibitor-1)
production in endothelial cells,
25
an increase in
thromboxane secretion in endothelial cells,26 and
an increase in arterial smooth muscle intracellular
calcium.27
Several large prospective studies have ex-
amined the relationship between sd-LDL and CAD
using gradient gel electrophoresis to determine the
peak particle size. These found the odds ratio of
CAD to increase significantly when sd-LDL was
the predominant LDL subclass present.28-30 Evid-
ence from several angiographic clinical trials indi-
cated that successful treatment correlated to a
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decrease in the number of sd-LDL particles.31-35
Data regarding the relationship of LDL particle
size to the coronary artery disease incidence are
limited in the Korean population. Moreover, data
on the relationship between LDL particle size and
the extent of coronary artery disease or acute
coronary syndrome (ACS) are limited worldwide.
Therefore, this study was performed to investigate
the relationship between LDL particle size and the
extent of CAD or acute coronary syndrome. In
addition, this study investigated the relationship
between LDL particle size and the Global risk
assessment score (GRAS) by using Framingham
risk score to determine whether sd-LDL can be
used as a cardiovascular event predictor.
MATERIALS AND METHODS
Subjects
This study enrolled 504 patients that underwent
coronary angiography at Yongdong Severance
Hospital, Yonsei University between October 2003
and June 2004. Any patients that had previously
undergone coronary angiography, had a history of
myocardial infarction, suffered chronic renal fail-
ure, were at endstage renal disease, suffered hepa-
tic failure, liver cirrhosis, an infectious disease or
had a malignancy were excluded from this study.
In addition, data derived from repeated coronary
angiography from the same patient were excluded.
Patients were considered hypertensive if they
had a known history of hypertension, systolic
blood pressure over 140 mmHg and/or diastolic
blood pressure over 90 mmHg. Patients were con-
sidered diabetic if they had a fasting serum glucose
over 126 mg/dL or if they were being treated with
oral hypoglycemic agents or insulin. The height
and weight of all subjects were recorded and a
body mass index (BMI) was calculated with the
formula: weight(kg) height
2
(m
2
).
9
The control group included men and women
showing normal or minimal CAD by coronary
angiogram. The CAD group was divided into an
ACS group and a non-ACS group. Diagnoses of
myocardial infarction and angina pectoris were
made based on: clinical symptoms, EKG changes
and/or biochemical markers. CAD was defined as
stenosis of one or more coronary artery branch
with 50% of the diameter or more luminal nar-
rowing as seen by coronary angiography.9
Estimation of the extent of CAD
The CAD extent was described by Gensini
scores.36 The Gensini score is a measure of the
extent of myocardial ischemia. These were com-
puted for each coronary artery stenosis, based on
the degree of luminal narrowing and the geo-
graphic importance of the stenosis.
Global risk assessment scoring
A 10-year risk of major coronary events was
calculated using the Framingham scoring system,
based on Framingham Heart Study.37,38
Lipoprotein and metabolic parameter analysis
Fasting blood samples were obtained by veni-
puncture on the day of the coronary angiography
prior to cardiac catheterization. Total cholesterol,
triglyceride, HDL cholesterol, and LDL cholesterol
were measured by the direct enzymatic method.
The LDL subfraction was analyzed by poly-
acrylamide tube gel electrophoresis (Quantimetrix
LipoprintTM LDL system, Redondo Beach, CA,
USA).39 It was then categorized as either pattern
A or B based on the mean LDL particle size. The
sd-LDL (subtypes 3-7) percentage of total LDL
was measured.
LDL subtypes 1-2 were predominantly large,
buoyant LDLs, whereas subtypes 3-7 were pre-
dominantly small, dense LDLs. The mean LDL
particle size for 'Pattern A' was greater than 26.5
nm, hence named 'large, buoyant LDL dominant',
while the mean value of particle size for 'Pattern
B' was less than 26.5 nm, thus named 'small, dense
LDL dominant'.
Statistical analysis
Statistical analyses were performed using SPSS
11.0 for Windows (SPSS Inc., IL, USA). Compari-
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sons between the control and CAD groups were
performed using a Student's t-test. All values are
described as the mean ± standard deviation. Sta-
tistical significance was defined as p < 0.05.
The extent of CAD was evaluated by reviewing
the coronary angiogram and was measured by the
Gensini score. The extent of CAD, ACS and mean
LDL particle size were investigated by multi-
variate analysis.
RESULTS
Comparison between the CAD patients and the
controls
The demographic and metabolic characteristics
of all patients are shown in Table 1. No differ-
ence was seen between CAD and control groups
in BMI, total cholesterol, or triglyceride levels. A
significant difference between the two groups
was seen in age, hypertension, incidence of dia-
betes mellitus, LDL cholesterol, HDL cholesterol,
mean LDL size, and sd-LDL fraction. The
patients with angiographically proven CAD had
a smaller mean LDL particle size than the control
group (26.41 ± 0.95 vs 26.73 ± 0.64 nm, p<0.001)
(Table 2).
Multivariate analysis of risk factors for CAD
A multiple logistic regression analysis revealed
small, dense LDL fraction to be an independent
risk factor for CAD (odds ratio [OR] 2.312, 95% CI
Table 1. Comparison of the Baseline Demographic and Metabolic Characteristics between CAD and Control Groups
Control (n = 242) CAD (n = 262) p value
Age (yr) 57.4 ± 11.6 63.1 ± 11.0 < 0.001
BMI (kg/m2) 25.1 ± 3.5 24.4 ± 3.3 0.037
Hypertension (%) 40.9 57.3 < 0.001
Current smoker (%) 27.3 39.4 0.005
DM (%) 11.6 32.4 < 0.001
hs-CRP (mg/dL) 7.6 ± 22.7 10.5 ± 28.5 NS
T. chol (mg/dL) 172.9 ± 34.1 178.5 ± 38.3 NS
TG (mg/dL) 132.0 ± 73.6 144.5 ± 76.3 NS
HDL chol (mg/dL) 44.9 ± 11.9 41.1 ± 10.1 < 0.001
LDL chol (mg/dL) 102.1 ± 29.4 109.2 ± 35.7 0.015
Framingham score 11.0 ± 4.9 13.9 ± 3.1 < 0.001
Data are expressed as mean ± SD.
Control, normal control group; CAD, coronary artery disease group; DM, diabetes mellitus; BMI, body mass index; hs-CRP,
high-sensitivity c-reactive protein; T. chol, total cholesterol; TG, triglyceride; HDL chol, high-density lipoprotein; LDL chol, low-density
lipoprotein; NS, not significant.
Table 2. Comparison of the LDL Cholesterol Characteristics between the CAD and Control Groups
Control (n = 242) CAD (n = 262) p value
Mean LDL size (nm) 26.73 ± 0.64 26.41 ± 0.95 < 0.001
LDL class (A/B) (%) 74.4 / 25.6 51.1 / 48.9 < 0.001
Fraction % of sd-LDL 12.2 ± 13.9 18.2 ± 18.0 < 0.001
Data are expressed as mean ± SD or percentage of total LDL.
Control, normal control group; CAD, coronary artery disease group; LDL, low-density lipoprotein; A, pattern A; B, pattern B; sd-LDL,
small dense LDL.
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1.512-3.537, p < 0.001) (Table 3).
Correlation between CAD severity and the mean
LDL particle size
There was a significant difference in the mean
Gensini scores between patients with pattern A
and B LDL (14.4 ± 22.9 vs 24.1 ± 28.9, p < 0.001)
(Fig. 1A). A univariate linear analysis between
mean LDL particle size and the Gensini score
showed a significant negative correlation (Cor-
relation coefficient = -0.188, p < 0.001) (Fig. 1B).
Correlation between the mean LDL particle size
and Framingham risk score
The mean LDL particle size showed a signifi-
cant negative correlation with Framingham risk
score (correlation coefficient = -0.121, p = 0.007)
(Fig. 2).
Analysis between ACS and non-ACS CAD
patients
The demographic and metabolic characteristics
of the ACS and non-ACS groups are shown in
Fig. 1. (A) Comparison of pattern A and B mean Gensini scores. Mean Gensini scores for patterns A and B were
significantly different (14.4 ± 22.9 vs 24.1 ± 28.9, p < 0.001). Pattern A represents a predominance of large, buoyant LDLs
(mean particle size greater than 26.5 nm). Pattern B represents a predominance of small, dense LDLs (mean particle size
smaller than 26.5 nm). (B) Correlation between mean LDL particle size and Gensini score. The mean LDL particle size had
a significant negative correlation with the Gensini score (r = -0.188, p < 0.001). r, correlation coefficient.
Table 3. Multiple Logistic Regression Analysis for CAD
OR 95% CI p value
Age (yr) 3.763 2.085 - 6.791 < 0.001
Obesity 0.811 0.537 - 1.224 NS
Smoking 1.835 1.186 - 2.838 0.006
Hypertension 1.521 1.009 - 2.293 0.045
Diabetes Mellitus 3.291 1.957 - 5.537 < 0.001
Low HDL chol 1.208 0.714 - 2.044 NS
High LDL chol 2.220 0.754 - 6.538 NS
sd-LDL (Pattern B) 2.312 1.512 - 3.537 < 0.001
OR, odds ratio; CI, confidence interval; HDL, high-density lipoprotein; LDL, low-density lipoprotein; chol, cholesterol; sd-LDL, small
dense LDL; NS, not significant.
A B
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Table 4. There was no significant difference seen
between ACS patients and non-ACS patients in
age, diabetes mellitus, BMI, total cholesterol, LDL
cholesterol, HDL cholesterol or triglyceride levels.
A significant difference between the groups was
noted in smoking, hypertension, mean LDL par-
ticle size, and sd-LDL fraction. The mean LDL
particle size was smaller in the ACS group than
the non-ACS group (26.09 ± 1.42 vs 26.54 ± 0.63
nm, p = 0.011) (Table 5).
Multivariate analysis of risk factors for ACS
A multiple logistic regression analysis showed
that small dense LDL is not an independent risk
factor for ACS (odds ratio [OR] 1.394, 95% CI,
0.765-2.540, p = NS) (Table 6).
DISCUSSION
Gradient gel electrophoresis under native condi-
tions is commonly used to characterize LDL par-
ticle size distribution.40 Densitometric LDL sub-
fraction scans show a bimodal distribution. Pat-
tern A LDL is characterized by a predominance of
large, buoyant LDL particles with a major LDL
diameter peak greater than 25.5 nm. Pattern B
LDL is characterized by a predominance of sd-
LDL particles with a major peak less than 25.5 nm.
41-43 sd-LDL is often accompanied by triglyceride,
increased apo B and decreased high-density lipo-
protein (HDL) levels. These dysliproproteinemia
are somewhat correlated to increased risk of CAD
Fig. 2. Correlation between mean LDL particle size and
Framingham risk score. The mean LDL particle size had
a negative correlation with GRAS (r = -0.121, p = 0.007).
GRAS (global risk assessment score) was obtained by
using the Framingham risk scoring method; LDL, low-
density lipoprotein; r, correlation coefficient.
Table 4. Comparison of the Demographic and Metabolic Characteristics between the ACS and Non-ACS Groups
Non-ACS (n = 188) ACS (n = 74) p value
Age (yr) 63.6 ± 10.06 61.8 ± 13.2 NS
BMI (kg/m2) 24.6 ± 3.4 23.9 ± 3.1 NS
Hypertension (%) 62.2 44.6 0.012
Current smoker (%) 35.6 49.3 0.048
DM (%) 33.0 31.1 NS
hs-CRP (mg/dL) 7.2 ± 23.7 18.4 ± 36.7 0.019
T. chol (mg/dL) 178.9 ± 36.5 177.4 ± 42.5 NS
TG (mg/dL) 145.1 ± 74.8 142.9 ± 80.3 NS
HDL chol (mg/dL) 41.1 ± 10.0 41.0 ± 10.4 NS
LDL chol (mg/dL) 109.2 ± 33.5 109.4 ± 40.9 NS
Framingham score 14.0 ± 2.8 13.6 ± 3.6 NS
Data are expressed as mean ± SD.
ACS, acute coronary syndrome; DM, diabetes mellitus; BMI, body mass index; hs-CRP, high-sensitivity c-reactive protein; T. chol,
total cholesterol; TG, triglyceride; HDL chol, high-density lipoprotein; LDL chol, low-density lipoprotein;A, pattern A; B, pattern
B; NS, not significant.
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development. It is not clear, however, whether sd-
LDL's influence on CAD development is de-
pendent on any other factors, including changes
in lipoproteins and lipid parameters.
Our results indicate that the sd-LDL fraction of
total LDL is significantly associated with CAD.
This association is seen in both males and females.
Even after adjustment for traditional risk factors,
such as: age, obesity, smoking, diabetes mellitus,
HDL cholesterol level, and LDL cholesterol level,
our multiple logistic regression analysis still
showed a significant correlation between sd-LDL
and CAD. These findings suggest that sd-LDL can
be viewed as an independent risk factor for CAD
development apart from the traditional risk fac-
tors.
By using the Gensini score, the present study
was able to investigate the correlation between
mean LDL particle size and the extent of CAD.
Several reports have suggested that sd-LDL may
be an independent CAD risk factor and might
contribute to CAD severity. These reports simply
used the number of diseased coronary arteries as
a measure of CAD severity.
5,44
One study reported
the sd-LDL prevalence to be strongly associated
with various CAD types. This study also found
sd-LDL to be independent of traditional and
nontraditional coronary risk factors. The study did
not show, however, whether sd-LDL was related
to the severity and extent of coronary artery
lesions as indicated by Gensini scores.43 The
present study used the Gensini score as a measure
of extent of CAD. Therefore, the present study is
the first study to provide evidence of a significant
correlation between mean LDL particle size and
extent of CAD, as depicted by Gensini scores.
Gensini scores should provide a more objective
parameter than the number of diseased coronary
arteries.
Many studies have analyzed the relationship
Table 5. Comparison of the Characteristics of LDL Cholesterol between the ACS and Non-ACS Groups
Non-ACS (n = 188) ACS (n = 74) p value
Mean LDL size (nm) 26.54 ± 0.63 26.09 ± 1.42 0.011
LDL class (A/B) (%) 53.2 / 46.8 45.9 / 54.1 NS
Fraction % of sd-LDL 16.5 ± 15.0 22.9 ± 23.6 0.034
Data are expressed as mean ± SD or percentage of total LDL.
ACS, acute coronary syndrome; LDL, low-density lipoprotein; A, pattern A; B, pattern B; sd-LDL, small dense LDL; NS, not
significant.
Table 6. Multiple Logistic Regression Analysis for ACS
OR 95% CI p value
Age 0.961 0.336 - 2.746 NS
Obesity 0.464 0.248 - 0.867 0.016
Smoking 2.135 1.163 - 3.922 0.014
Hypertension 0.600 0.334 - 1.077 NS
Diabetes Mellitus 0.891 0.477 - 1.665 NS
hs-CRP 1.010 1.000 - 1.021 NS
Low HDL chol 0.980 0.498 - 1.930 NS
High LDL chol 1.026 0.299 - 3.519 NS
sd-LDL (Pattern B) 1.394 0.765 - 2.540 NS
OR, odds ratio; CI, confidence interval; hs-CRP, high-sensitivity c-reactive protein; HDL, high-density lipoprotein; LDL, low-density
lipoprotein; chol, cholesterol; sd-LDL, small dense LDL; NS, not significant.
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between triglyceride, LDL cholesterol, LDL par-
ticle size and CAD prevalence. Among these,
acute myocardial infarction has been shown to
have a strong negative correlation with high trig-
lyceride concentrations and LDL particle size.45-48
Several reports have suggested a negative cor-
relation between LDL particle size and risk of
acute myocardial infarction.29,46 Furthermore, a
negative association between LDL particle size
and CAD development in general has also been
reported.49,50 When data were adjusted for trigly-
ceride levels, these reports failed to prove that
LDL particle size is an independent CAD risk
factor. Meanwhile, other studies have demon-
strated that the association between CAD and
sd-LDL is independent of triglyceride level.44,51
Our study revealed that LDL particle size is signi-
ficantly correlated with total cholesterol, trigly-
ceride, HDL cholesterol, and LDL cholesterol.
After running the Student's t-test, however, no
significant difference was seen in triglyceride level
between the CAD and control groups. This is
probably due to the relatively large variations in
triglyceride level.
We also studied the correlation between mean
LDL particle size and global risk assessment score
(GRAS). There was a significant negative correla-
tion between these two parameters. This result
suggests that further studies are required to deter-
mine whether sd-LDL is a reliable 10-year pre-
dictor of coronary event risk.
sd-LDL is associated with increased triglyceride
and decreased HDL levels.
52
The LDL size and
density are partly affected by the exchange of
triglycerides at the expense of cholesteryl esters
from LDL, possibly mediated by cholesteryl ester
transfer protein. This process causes LDL to
become enriched in triglycerides at the expense of
cholesteryl esters. Excess triglycerides in the LDL
particle allows continued size reduction by he-
patic triglyceride lipase, which may result in lipid-
poor, thus, protein-rich LDL particles of relatively
high density.53 In addition to the addition of
triglycerides, it has been suggested that genetic
factors and increased hepatic lipase and lipid
transfer activities also contribute to LDL hetero-
genicity. A carbohydrate-rich diet is also known
to be associated with an increased sd-LDL level.
Increased carbohydrate intake causes free fatty
acid synthesis in the liver, which can, potentially,
stimulate large triglyceride-rich VLDL produc-
tion.54
LDL particle size seems to be more stable, and
less influenced by meals than triglyceride levels,
although fasting samples are needed for more
definitive results. Therefore, LDL particle size is
better than triglyceride levels at predicting the
development of coronary artery disease. The pro-
blem is that the LDL subfraction is more difficult
to measure than triglyceride levels. Conventional
methods for measuring LDL subfractions, such as
density gradient ultracentrifugation, native gra-
dient gel electrophoresis, and nuclear magnetic
resonance spectroscopy are not suitable for a clini-
cal laboratory setting because they are labor inten-
sive, require skillful and experienced technicians,
are poorly reproducible and take a significant
amount of time to analyze. The recently devel-
oped Quantimetrix LipoprintTM LDL system uses
polyacrylamide tube gel electrophoresis and
provides more benefits than previous methods.
Using this method, LDL subfractions can be easily
analyzed in a short time.55
This study also investigated the correlation
between sd-LDL and ACS. The CAD group was
divided into an ACS and non-ACS group. The
mean LDL particle size was smaller in the ACS
group than the non-ACS group. The sd-LDL, as
a percentage of total LDL, was higher in the ACS
group than the non-ACS group. The multivariate
analysis did not support the hypothesis that LDL
particle size is an independent risk factor for ACS
development. When we compared the lipid pro-
files of the ACS and non-ACS groups using a
Student's t-test, we found no significant differ-
ence. The fact that the blood samples were col-
lected on the day of coronary angiography might
have affected LDL or HDL values. Several studies
have reported a significant decrease in lipid pro-
files during the acute phase of acute coronary
events.56-59
Lipoprotein (a) (Lp (a)) and oxidized LDL are
modified forms of LDL that may also play im-
portant roles in the CAD development. Lp (a)
accumulates in atherosclerotic lesions, accelerates
smooth muscle proliferation and downregulates
glucocorticoid receptors. Lp (a) levels are elevated
in CAD and contributes to restenosis after angio-
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plasty.60 The relationship between LDL particle
size and Lp (a) have not yet been fully explored.
Malondialdehyde-modified LDL (MDA-LDL), an
oxidized LDL candidate, could be a useful CAD
indicator. MDA-LDL levels are, reportedly, signi-
ficantly associated with LDL particle size. It has
been suggested that circulating MDA-LDL plays
an important role in atherosclerosis pathogenesis
and might become a new therapeutic target for
CAD prevention.61 Further studies are needed to
identify the relationship between MDA-LDL and
CAD and ACS development.
Although a recent study reported that an LDL
size increase was seen after intensive lipid-low-
ering therapy, and its decrease was strongly asso-
ciated with CAD progression.31 Further studies
are needed to determine if there is a correlation
between LDL particle size and the progression or
regression of CAD and ACS. Further studies need
to be done on patients after intensive lipid-lower-
ing therapy to determine whether LDL particle
size or cholesterol level is more important in CAD
and ACS development. Furthermore, it would be
interesting to examine CAD patients after percu-
taneous coronary intervention and explore the
relationship between LDL particle size and reste-
nosis.
In summary, LDL particle size was smaller
among CAD patients, and correlated with the
extent of CAD and ACS. The present study
demonstrates that sd-LDL levels are strongly
associated with CAD, are independent of both
traditional and nontraditional coronary risk
factors and are related to the extent of coronary
lesions. Furthermore, sd-LDL plays an important
role not only in the onset of CAD, but also in the
progression of the disease.
In conclusion, sd-LDL is independently asso-
ciated with the incidence and extent of CAD, and
may be a risk factor for CAD and ACS develop-
ment in the Korean population.
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